Pursuant to Standing Order 108(2) and the motion adopted by the committee on Tuesday, September 23, 2025, the committee shall resume its study of Canada's pharmaceutical sovereignty.
The committee suspended its meeting on Thursday, May 7, 2026, after a question of privilege was raised by Dr. Strauss. Therefore, we are resuming this meeting, and I will render my decision.
Madam Sidhu, do you want to say something before I give my—